SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (Nasdaq: SABS) is a clinical-stage biopharmaceutical company focused on developing fully human polyclonal antibodies using its proprietary DiversitAb platform, which employs genetically engineered cattle as a production system. The company went public in October 2021 through a merger with Big Cypress Acquisition Corp., a blank-check company sponsored by Big Cypress Holdings LLC. Headquartered in Sioux Falls, South Dakota, SAB operates in the biotechnology and immunotherapy sector, with a pipeline targeting infectious disease, metabolic disorders, and immune-mediated conditions. The company continues to file periodic reports with the SEC, most recently submitting a 10-Q on August 6, 2026. Sign up at SpacDesk for complete filings, financial data, and deal history on SABS and hundreds of other SPAC-originated companies.